TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN clinical trials

ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer

This study looks at a new way to treat an advanced type of breast cancer (HER2-low triple-negative breast cancer). It combines two existing medicines, sacituzumab govitecan and trastuzumab deruxtecan, given in an alternating pattern, to see if this helps people live longer.